



GOOD PEOPLE
for GOOD HEALTH

August 4, 2022

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G-Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Subject: Investor Presentation

Enclosed please find the presentation the Company proposes to make to investors/analysts on financial performance for the quarter ended on June 30, 2022.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President - Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:


J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

www.jbpharma.com



JB Pharma - Q1 FY23 Financial Results

August 4, 2022



Disclaimer



No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management JB Chemicals & Pharmaceuticals Limited ("Company" or "JB Pharma" or "JB Chemicals & Pharmaceuticals Limited"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from. This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.



Corporate Overview

Corporate Snapshot



46

Years of operations with consistent track record across multiple businesses

40+

Regulated/semi-regulated markets of presence through direct operations and distributors

24%

Growth in chronic therapies* in the domestic formulations business

7

Multi-dosage formulation plants with key global approvals/compliances

5

Brands among top 300 brands, contributing over 60% of domestic formulations revenues

Top 5

Global manufacturer of medicated/herbal lozenges representing a substantial opportunity

#2500

Strong India field force with therapy-focused segmentation

**22%

ROCE with consistent cash flow generation generating good returns




* CAGR over FY20-FY22 (IQVIA MAT March data)


Includes MR and Supervisors

** ROCE for FY22 $ROCE = EBIT / (Net\ Worth + Debt - Mutual\ Fund\ Investments)$

Corporate Snapshot – Financial Overview



Increasing Share of the Domestic Revenue



*Operating EBITDA is after excluding non-cash ESOP Charge

World Class Manufacturing Facilities



Seven state-of-the-art manufacturing facilities in Western India

Over 40 global regulatory accreditations

US FDA	EU – GMP
HEALTH – Canada	SAHPRA – South Africa
MHRA – UK	TGA – Australia
MOH – Russia	

Producing a wide array of dosage forms





Q1 FY23 Business Performance

CEO's Message



Nikhil Chopra,
CEO & Whole Time Director



*Views on Q1 FY23 business
performance*

“Our operating performance in FY23 started on a strong note. We continued the momentum in our domestic business, registering market beating growth and achieving a new milestone in quarterly run-rate revenue of over INR 400 crore. Integration of Sanzyme's product range and Azmarda have progressed as per plan. We also completed the acquisition of a portfolio of paediatric brands which will enable us to offer a more comprehensive product basket to paediatricians, helping us to serve them better. International business also saw strong growth with a robust order pipeline and out-performance in the CMO segment. With this start, I believe we have built good momentum for the year ahead and together with our continued focus on productivity enhancement and cost optimisation, we are confident of delivering profitable growth.”

Financial Overview Q1 FY23 vs Q1 FY22



Revenues (INR cr)



- JB recorded robust revenue growth at 30% despite a challenging operating environment
 - Organic revenue growth was around 20%
- Domestic Formulations business continued its strong performance growing at 34% to INR 418 cr
 - Organic revenue growth was around mid-teens
- International business revenue grew at 28% to INR 366 crores
 - All the three businesses viz. Exports formulations, CMO and API business performed well in the quarter


EBITDA Analysis




INR crore	Q1 FY23	Q1 FY22	FY22	
Revenue	785	606	2424	
Reported EBITDA	173	164	543	
Non Cash ESOP Cost	17	-	62	Included in Employee Benefits expense
Operating EBITDA (excluding ESOP Cost)	190	164	605	
Operating EBITDA Margin	24.2%	27%	25%	

Financial Overview Q1 FY23 vs Q1 FY22

Op. EBITDA* (INR cr)



Profit After Tax (INR cr)



** Op EBITDA as a % to Sales


* Operating EBITDA excluding non-cash ESOP Charge

- Operating EBITDA* grew by 16% to INR 190 crores
- Gross margins were at 62.7% v/s 64.2%
 - Excluding Azmarda, gross margins for the business were relatively flat YoY
 - Overall material cost continues to remain challenging whilst softening was seen in certain packing material
- Excluding non-cash ESOP cost, employee cost increased by 19% due to increments and manpower cost for acquired brands
 - Non-cash ESOP cost as a percentage to reported EBITDA was at 10% as compared to 20% of reported EBITDA in Q4 FY22
- Other expenses increased on account of
 - Normalization of marketing expense as compared to Q1 FY22
 - Significant increase in fuel costs, freight expenses and logistics costs for the exports business on a YOY basis, whilst sequentially some softening was seen in international freight
- Depreciation increased by 44% to INR 26 crores on account of amortization of the acquired brands
- PAT declined by 12% to INR 105 crores on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23



Domestic Business Q1 FY23 vs Q1 FY22

Domestic Formulations (INR cr)



- Domestic Business records highest ever sales in a quarter of INR 418 crore registering growth of 34%
- Organic revenue from the domestic business grew around mid-teens out-pacing industry growth rate
- JB continues to remain the fastest growing company among the top 25 as per IQVIA MAT June 22 data
- As per MAT June 22 data, JB ranks 23rd as compared to 25th in Q4 FY22
- The acquired brands from Sanzyme performed well with Sporlac gaining market share during the quarter
- Successful transition of the acquired brand Azmarda; good revenue traction achieved
- As compared to IQVIA MAT June 22 vs MAT June 21 data
 - Metrogyl has gained 27 ranks to #165
 - Cilacar-T has gained 95 ranks to #190
 - Nicardia has gained 13 ranks to # 220
 - Cilacar was at #49 and Rantac was at #41

JB continues to be the fastest growing company in IPM, maintaining market beating performance



Fastest growing company among the Top 25 in the IPM

Outperformed the CVM growing at 24% vs 9% CVM growth

Organic business grew at 23%

Market beating growth

24% Vs IPM growth of 8%

Leadership position in the covered markets

35% + share in 7 molecule categories

Position in IPM

23rd Rank in IPM


No of brands in Top 300

5 Brands, with average growth registered @ 20+%

Growth rates and Ranking as per IQVIA MAT June'22 Numbers



Prescription wise JB now Ranks #15




* Nos in Lakhs
** Nos in '0000

#15 Prescription Ranking

- JB now ranks #15 in IPM as per IQVIA prescription data gaining one rank (IQVIA MAT June'22 vs MAT June'21)
- JB's prescription base increased from 2.61 cr prescriptions in Q1 FY22 to 4.09 cr in Q1 FY23, growing at 57%
- This was aided by increased prescriptions from existing prescribers as well as significant addition in the number of prescribers
- The P/D ratio also improved sharply from 36 to 50 YoY

All Data as per IQVIA

International Business Q1 FY23 vs Q1 FY22



- International business recorded robust revenue growth of 28% to INR 366 crores
 - Exports formulations, CMO and API business recorded growth of 11%, 108% and 17% respectively
- South Africa unit registered growth in both public & private markets; robust tender demand; new launches in private market
- Russia local sales remained steady; Receivables looking positive from the region
- CMO revenue crossed INR 100 crores for the first time in a quarter due to strong surge on account of demand in lozenges and liquids from key partners
 - Order book continues to remain robust



Financial Performance (Consolidated)

Particulars	Q1 FY23	Q1 FY22	YoY Growth	FY22	FY21	Growth
Revenue from Operations	785	606	30%	2424	2043	19%
Cost of Goods Sold	293	217	35%	843	701	20%
Gross Profit	492	389	26%	1581	1341	18%
Gross Profit Margins	62.7%	64.3%		65.2%	65.7%	
Employee Benefit Expenses	134	98	37%	439	341	29%
Other Expenses	185	128	45%	599	440	36%
EBITDA	173	164	6%	543	560	-3%
Finance Costs	6	1		5	7	-29%
Depreciation	26	18	44%	73	69	6%
Profit before Tax (Operating)	141	145	-3%	466	485	-4%
Other Income	1	13		39	112	-65%
Profit before Tax	142	158	-10%	505	597	-15%
Tax Expenses	37	39	-5%	119	148	-20%
Profit after Tax	105	119	-12%	386	449	-14%



Further Expanding Our Product Range -Acquisition of the Paediatric Portfolio

Acquisition of Paediatric Brands: Leveraging on Existing Capabilities



Business Overview

- JB acquired 4 Paediatric brands from Dr Reddy's
- Internal sales of INR 33 cr in FY22
- 3 out of 4 brands are among the top 3 players in respective molecules with Z&D and Pedicloryl being market dominators.
- These brands were not the primary focus brands in the seller's large divisions
- Complements JB's Paedia division with minimal additional manpower and marketing spends.

Key Brands

Market

Market Share*

FY22 sales*


Pedicloryl	Triclofos Hypnotic agent used in Paediatric Insomnia/Idiopathic Pain	MS 76%	9 Crs
Z&D	Zinc nutritional supplements Used as a supplement for children aids in absorption of minerals such as calcium and Zinc	MS 59%	18 Crs
Ezinapi	Emollient blend of Cetyl myristoleate, Zinc oxide, D-panthenol used as an emollient for diaper rash.	MS 12%	4 Crs
Peccef	Anti-biotic Cefpodoxime & combinations used in infections of lung, eyes, ears, nose, throat and GI	MS 1-2%	16.1 Crs

*IQVIA MAT Mar'22 data


Paediatric segment continues to be a promising segment driving IPM growth, expected to reach 18,000 Crs by 2025

After a significant Covid impact, Paedia market has bounced back strongly, with a 10% Rx growth...

Paedia Rx trends, in Crs




Paedia Rxber trends, in '000s



...propelling sales that is expected to grow at 12% reaching 18,000 Crs in the next 3 years

Paedia IPM sales, in INR Crs*



Paedia contributes to ~7% of IPM. The market posted a strong recovery after a flat FY21.

Source: IQVIA Sales TSA MAT May'22, Rx audit Apr'22

*Estimated based on Rx contribution

JB Strengthening its Presence Across all major Paediatric Therapeutic Areas



Covering all major Paediatric therapeutic areas



Anti-infectives	Gastro and Gut	Skin & Wound	Anti-parasitic	Idiopathic Pain/ Insomnia	Pro-biotics
✓	✓	✓	✓	✓	✓
Pecef/ Duo Ofm	Rantac Laxolite Z&D	Metrogyl P/ DG Ezinapi	Metrogyl range	Pedicloryl	Gutpro Sporlac

Existing JB portfolio DRL portfolio

JBs paediatric portfolio will enjoy better market reach & will be part of a dedicated paedia division



ACQUISITION BENEFITS

Comprehensive Portfolio with well known brands to cater to paediatricians

Increased market coverage and will align with our Go To Market model

Productivity Leverage as existing manpower will be deployed to market these brands

JB Pharma – Looking ahead –FY 2023



Domestic business to consistently outperform market growth driven by:

- ❑ Big brands becoming bigger
- ❑ Market share and prescription gains in acquired portfolio of probiotics, heart-failure & paediatric segment
- ❑ Life cycle management and new launches



Continued growth momentum in international business

- ❑ Strong delivery in CMO business aided by new launches
- ❑ Healthy private/ public business mix in S Africa
- ❑ Demand revival in specific ROW markets



Continuous thrust on cost optimization initiatives to deliver EBITDA margins (excl ESOP cost) in mid-twenties, despite inflationary pressure and external market uncertainties



About JB Pharma

J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on J.B. Pharma, please visit www.jbpharma.com.



For further information, please contact:

Lakshay Kataria, Chief Financial Officer

J B Pharma

Tel: +91 22 2439 5200 / 2439 5500

Email: lakshay.kataria@jbpharma.com

Jason D'Souza, Vice President

J B Pharma

Tel: +91 982 021 5005

Email: jason.dsouza@jbpharma.com

Siddharth Rangnekar / Shruti Joshi

CDR India

Tel: +91 976 991 9966/ +91 750 656 7349

Email: siddharth@cdr-india.com / shruti@cdr-india.com



Thank you



www.jbpharma.com